期刊
CELL BIOLOGY INTERNATIONAL
卷 39, 期 3, 页码 246-252出版社
WILEY-BLACKWELL
DOI: 10.1002/cbin.10383
关键词
arginine deprivation; cancer; metabolic therapy
类别
资金
- Polish Ministry of Science and Higher Education [N303318239]
- North Atlantic Treaty Organization [NUKR.SFPP 984173]
- integrated scientific Program of the National Academy of Science of Ukraine Sensors for Medical, Environmental, Industrial, and Technological Needs: Metrological Support and Trial Operation [5/3-2013]
- Innovation project of NAS of Ukraine [41]
Tumor cells often exhibit specific metabolic defects due to the aberrations in oncogene-dependent regulatory and/or signaling pathways that distinguish them from normal cells. Among others, many malignant cells are deficient in biosynthesis of certain amino acids and concomitantly exhibit elevated sensitivity to deprivation of these amino acids. Although the underlying causes of such metabolic changes are still not fully understood, this feature of malignant cells is exploited in metabolic enzymotherapies based on single amino acid, e.g., arginine, deprivation. To achieve efficient arginine depletion in vivo, two recombinant enzymes, bacterial arginine deiminase and human arginase I have been evaluated and are undergoing further development. This review is aimed to summarize the current knowledge on the application of arginine-degrading enzymes as anticancer agents and as bioanalytical tools for arginine assays. The problems that have to be solved to optimize this therapy for clinical application are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据